Sanofi (SNY)
(Delayed Data from NSDQ)
$46.97 USD
+0.11 (0.23%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $46.98 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNY 46.97 +0.11(0.23%)
Will SNY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Other News for SNY
Sanofi’s Tzield Gains Approval in China for Type 1 Diabetes
Former CDC Director Monarez says RFK Jr. fired her for not following two directives
Technical picture remains unchanged for SNY after it rises 0.51% on September 16
Berenberg Bank Sticks to Its Buy Rating for Sanofi (SNYNF)
J.P. Morgan Keeps Their Buy Rating on Sanofi (SNYNF)